Breaking the Spell: Checkpoint Inhibitors Help Microglia Snap Out of It
In ApoE4 carriers, checkpoint proteins Itgb8 and TIM3 lock microglia into homeostasis. Remove the lock, and they spring into neuroprotective action.
ALL NEWS
6654 RESULTS
Sort By:
- Most Recent
- Most Commented
Shingles Vaccine Deflects Dementia in Aussies, Too
Scientists corroborate their recent finding that shingles vaccination reduces dementia risk in a second population.
Triple Trouble: New Knock-in Turbocharges Tauopathy
Adding the S320F mutation to existing double-knock-in mice exacerbates tau pathology.
Therapies Aim to Tame T Cells in the Brain
At AD/PD, a handful of early trials showcased approaches to counteract harmful cytotoxic T cell responses in AD and related diseases.
Killers in the Crosshairs: Zeroing in on Invading CD8+ T Cells
Antigens from the brain can tickle T cells in cervical lymph nodes, instigating a cytotoxic invasion. With ApoE4, more T cells enter.
Leqembi in the Clinic: So Far, ARIA Echoes Trials
At AD/PD, clinicians from the U.S. and Israel shared data from a few hundred patients, reporting ARIA rates equal to, or lower than, those in trials.
European Commission Greenlights Leqembi, at Last
The marketing authorization comes after delays and reversals. It excludes APOE4 homozygotes and people taking anticoagulants, and requires a post-market study.
Delivery Courier? Microglia Drop Neprilysin Off Near Plaques in Brain
The cells reduced the amount of amyloid and improved downstream aspects of Alzheimer’s pathogenesis in mouse models.
Trontinemab Fuels Hope for Brain Shuttle Lift-Off
The TfR-targeted, anti-Aβ antibody swiftly axed amyloid throughout the brain. It caused little ARIA, but lots of infusion reactions.
Will We Soon Stage Alzheimer’s With Plasma Markers?
Tau fragments, alone or with other proteins, help identify people with lots of tangles. This may help select people for trials or therapy.
Blood Tests: Not Just for the Impaired?
Real-world data hints that plasma markers can pick up Alzheimer’s pathology before people have memory complaints.
Looking Good: Immunoassays for Blood Markers
Fully automated test may be as accurate as mass spec, and more scalable.
Tau PET as Progression Marker: It’s the Spread, Not the Brightness
The spatial extent of tau pathology better correlates with disease severity, and stages disease more accurately, than does tangle load.
Commander Complexes in Lysosomes Stave Off Parkinson’s Risk
Decreased lysosomal efficiency could result from shifts in endosomal recycling.
Trial-Eligible Genetic Variants Now Marked in Alzforum Mutations Database
DIAN-TU explains how it selects APP, PSEN1, and PSEN2 genetic variants for clinical trial inclusion.
Current Filters
No filters selected